Author Archives: Bruno Quinney

Structure of the eye
#Biotech #Financing #Stargardt disease

AAVantgarde Bio raises $141 million for IRD trials

Biotechnology company AAVantgarde Bio has raised $141 million to advance its clinical programmes in inherited retinal disorders (IRD) Stargardt disease and Usher 1B syndrome.  The investment follows a successful Series B financing round, led by Schroders Capital and existing investors Atlas Venture and Forbion.   AAVantgarde aims to use the proceeds to complete the clinical study of AAVB-039… Read More

#Business & Investment #News

Workcell with a microfluidic chip testing thousands of AI-designed proteins
#APAC #Nuclera #Protein

Nuclera expands eProtein Discovery access for APAC customers

Biotechnology company Nuclera has signed a partnership with life science provider Solve Scientific Australia, expanding access to eProtein Discovery for customers in Australia and New Zealand.  Nuclera says its eProtein Discovery System provides rapid and easy access to functional proteins. According to the company, by applying digital microfluidics alongside in situ protein detection assays and cell-free protein synthesis, eProtein Discovery reduces time and… Read More

#Business & Investment #News

#Dementia #GLP-1 #Lupus #Menopause

DDW Highlights: 4 November 2025

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week’s top story came from women’s health, as Bayer paved the way for… Read More

#Podcasts

Cancer research
#Clinical trial #FDA #nda

Relief Therapeutics announces positive results for PKU treatment 

Biopharmaceutical company Relief Therapeutics has announced positive results from its bioequivalence study of RLF-OD032 for the treatment of phenylketonuria (PKU).  The study achieved its primary pharmacokinetic endpoints, demonstrating that RLF-OD032 is bioequivalent to KUVAN Powder, the reference listed drug, as defined by the US Food and Drug Administration… Read More

#News

MRI of the brain
#CDMO #epilepsy #Neurology

Neumirna and ten23 partner to advance epilepsy treatments

Biotechnology company Neumirna Therapeutics has announced its partnership with CDMO company ten23 health to advance treatments for epilepsy and other neurological diseases.  The companies will collaborate to advance NMT.001, a microRNA–targeting antisense oligonucleotide (ASO) designed to treat drug-resistant epilepsy, towards clinical development. The goal is to bring… Read More

#News

#Autoimmune disease #Monte Rosa Therapeutics #Preclinical development

Monte Rosa announces results for autoimmune disease treatment 

Biotechnology company Monte Rosa Therapeutics has released preclinical data on MRT-6160, a molecular glue degrader (MGD) to treat autoimmune and inflammatory diseases.  The findings reveal MRT-6160, a first-in-class VAV1-directed MGD, inhibited disease pathology, including proteinuria, lymphadenopathy, skin lesion formation, autoantibody production, and organomegaly in a spontaneous autoimmune… Read More

#News

Laboratory research
#Clinical development #Clinical trial #ischaemic stroke

Lumosa announces positive results from trial of stroke treatment 

Pharmaceutical company Lumosa Therapeutics has announced positive results from its Phase IIb clinical trial of LT3001 in patients with acute ischaemic stroke.  LT3001 met its primary endpoint of safety, with no treatment-related symptomatic intracranial haemorrhage (siCH) observed. The results showed that LT3001 maintained a favourable safety profile… Read More

#News

Child having ultrasound on knee
#Antibody drug conjugate (ADC) #Arthritis #Clinical trial

Lifordi begins human trial of RA treatment after positive results 

Biotechnology company Lifordi Immunotherapeutics has announced its Phase I study of rheumatoid arthritis (RA) treatment LFD-200 is underway, with positive initial results.  LFD-200 is a glucocorticoid antibody-drug conjugate (ADC) that delivers a potent steroid payload directly to immune cells, aiming to maintain the anti-inflammatory benefits of glucocorticoids… Read More

#News

Cancer tumour
#Cancer research #Clinical trial #Domain Therapeutics

First patients dosed in trial of novel tumour treatment

The first patients have been dosed in a Phase I/II trial of Domain Therapeutics’ DT-7012 targeting CCR8 in solid cancer tumours  DT-7012 is a novel immunotherapy candidate designed to selectively deplete intra-tumoural regulatory T cells (Tregs) by targeting CCR8, a receptor predominantly expressed… Read More

#News

#Artificial intelligence (AI) #Multiomics #Oncology

How AI and multiomics are accelerating drug discovery

DDW Editor Reece Armstrong speaks to Tyrone Lam, Chief Business Officer (CBO) at GATC Health, about how multiomics and AI can advance drug discovery in areas such as opioid use disorder (OUD).     RA: What are the current challenges of traditional drug development processes?   TL: Traditional drug development is often… Read More

#Exclusive Content

#Drug discovery #Drug screening #Merck #Promega

Merck and Promega to co-develop drug discovery technologies 

Merck has entered a partnership with global life science service Promega Corporation to co-develop technologies advancing drug screening and discovery.  The agreement will bring together Merck’s expertise in organoids and synthetic chemistry with Promega's assay and reporter technologies. The companies aim to develop assays capable of tracking cellular activity in… Read More

#Business & Investment #News

GSK offices
#Antibody drug conjugate (ADC) #Cancer research #GSK

GSK buys rights to develop ADC treatment for prostate cancer 

GSK has acquired exclusive rights from biotechnology company Syndivia to develop and commercialise an antibody-drug conjugate (ADC) in prostate cancer.  The global biopharma company aims to develop the ADC for metastatic castration-resistant prostate cancer (mCRPC), which remains a significant health burden for men.  Approximately 1.4 million men worldwide are diagnosed… Read More

#Business & Investment #News

Chinese flag
#Artificial intelligence (AI) #CDMO #China #Life sciences

CDMOs set for fastest growth in China and US, report finds 

The global outsourcing market is set to grow the fastest in China and the US but India has cooled its interest, analysis by Biobeat finds.  Published ahead of CPHI Frankfurt, the world’s largest CDMO conference, the analysis reveals the market has demonstrated resilience, with higher growth ahead predicted for mAbs,… Read More

#Business & Investment #News

#Antibody drug conjugate (ADC) #Cancer research #Oncology

Antibody-drug conjugates: A targeted approach in cancer therapy

Janet Sasso, Information Scientist at CAS, provides an overview of the antibody drug conjugate market and its potential in oncology.    Antibody-drug conjugates (ADCs) are a class of targeted biopharmaceuticals that combine the potency of cytotoxic drugs with the selectivity of monoclonal antibodies, a combination attracting growing attention in the… Read More

#Exclusive Content

#Drug discovery #Novel therapeutics

Fragment-based drug discovery: A unified workflow for efficient lead generation

Babu Boga, Vice President of Medicinal Chemistry and Xiang Li, President of the Chemical Division at BioDuro, explore the advantages of a unified FBDD workflow.    The pharmaceutical industry constantly seeks innovative methods to identify novel therapeutic agents. Traditional high-throughput screening (HTS) often faces challenges like high false-positive rates and… Read More

#Exclusive Content

#Artificial intelligence (AI) #AstraZeneca #Business #Cell therapy #Google #Immunotherapy

DDW Highlights: 28 October 2025

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, Galapagos announced plans to shelve its cell therapy business and hundreds of… Read More

#Podcasts